XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
Total
Adjustment
6.50% Convertible Senior Notes Due 2024
August 2019 Bonds
Preferred stock
Common stock
Common stock
6.50% Convertible Senior Notes Due 2024
Common stock
August 2019 Bonds
Additional paid-in capital
Additional paid-in capital
Adjustment
Additional paid-in capital
6.50% Convertible Senior Notes Due 2024
Additional paid-in capital
August 2019 Bonds
Accumulated deficit
Accumulated deficit
Adjustment
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2019         23 101,361,034                    
Beginning balance at Dec. 31, 2019 $ 5,404,858       $ 0 $ 101,361     $ 742,646,785       $ (739,785,655)   $ 472,608 $ 1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash, net of financing costs (in shares)           66,064,886                    
Issuance of common stock for cash, net of financing costs 454,486,400         $ 66,065     454,420,335              
Conversion of preferred stock/senior notes to common stock (in shares)         (14) 5,147 11,535,660 4,962,364                
Conversion of preferred stock/senior notes to common stock 0   $ 43,694,386 $ 102,671,310   $ 5 $ 11,536 $ 4,961 (5)   $ 43,682,850 $ 102,666,349        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           2,922,402                    
Exercise of stock options for cash and vesting of RSUs, net of tax payments 8,241,624         $ 2,923     8,238,701              
Stock-based compensation 15,647,523               15,655,585             (8,062)
Acquisition of non-controlling interest in Geneos, net 2,379,969                             2,379,969
Deconsolidation of Geneos (3,181,640)                             (3,181,640)
Net loss attributable to common stockholders (167,474,914)                       (166,411,157)     (1,063,757)
Dissolution of majority-owned subsidiary VGX Animal Health, Inc. 0               96,269             (96,269)
Unrealized loss on short-term investments, net of tax (755,963)                           (755,963)  
Foreign currency translation 27,205                           27,205  
Ending balance (in shares) at Dec. 31, 2020         9 186,851,493                    
Ending balance at Dec. 31, 2020 461,140,758       $ 0 $ 186,851     1,367,406,869       (906,196,812)   (256,150) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash, net of financing costs (in shares)           27,310,341                    
Issuance of common stock for cash, net of financing costs 209,441,410         $ 27,310     209,414,100              
Conversion of preferred stock/senior notes to common stock (in shares)           1,009,450                    
Conversion of preferred stock/senior notes to common stock 4,377,892         $ 1,009     4,376,883              
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           2,211,603                    
Exercise of stock options for cash and vesting of RSUs, net of tax payments 2,057,393         $ 2,212     2,055,181              
Stock-based compensation 26,336,764               26,336,764              
Net loss attributable to common stockholders (303,658,710)                       (303,658,710)      
Unrealized loss on short-term investments, net of tax 4,048                           4,048  
Foreign currency translation (30,134)                           (30,134)  
Ending balance (in shares) at Dec. 31, 2021         9 217,382,887                    
Ending balance at Dec. 31, 2021 399,669,421 $ (1,468,216)     $ 0 $ 217,382     1,609,589,797 $ (3,294,019)     (1,209,855,522) $ 1,825,803 (282,236) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock for cash, net of financing costs (in shares)           34,445,743                    
Issuance of common stock for cash, net of financing costs 82,955,311         $ 34,447     82,920,864              
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)           1,262,689                    
Exercise of stock options for cash and vesting of RSUs, net of tax payments (1,114,609)         $ 1,261     (1,115,870)              
Stock-based compensation 22,555,419               22,555,419              
Net loss attributable to common stockholders (279,818,065)                       (279,818,065)      
Unrealized loss on short-term investments, net of tax (390,949)                           (390,949)  
Foreign currency translation (25,556)                           (25,556)  
Ending balance (in shares) at Dec. 31, 2022         9 253,091,319                    
Ending balance at Dec. 31, 2022 $ 222,362,756       $ 0 $ 253,090     $ 1,710,656,191       $ (1,487,847,784)   $ (698,741) $ 0